Sterling expands in North Carolina
Following on from earlier acquisitions and investments on both sides of the Atlantic, Sterling Pharma Solutions has commenced a $2.1 million expansion project to increase chemical and analytical capabilities at its facility in Cary, North Carolina. The work should be completed by the end of 2022 and will create up to 20 new jobs. This will include five new laboratories: two for R&D, one for scaling up chemical synthesis and others for QC and analytical services.
The 2,500 m2 facility opened in 1994 and employs 50. It provides services to support API development and manufacturing product from pre-clinical through to Phase 2, including cGMP manufacturing, and capabilities to handle DEA schedule 1-5 controlled substances.
RELATED ARTICLES
Swiss CDMO Siegfried has inaugurated its new global R&D centre for drug substances at its site in Evionnaz.
Peptides CDMO AmbioPharm, has broken ground on a 650 m2, $28 million expansion project at its Shanghai manufacturing site. This is due to be complete in 2H 2025 and will produce over 8 tonnes/year of crude peptide.
Three CDMOs have separately announced expansions in their antibody-drug conjugate (ADC) manufacturing capabilities and capacity on opposite sides of the Atlantic.
Biosynth, which supplies critical raw materials and services for diagnostics, vaccines and pharmaceuticals, has officially opened its Biosynth Biological Technology site at Lifebay, a technology park in Suzhou, China.
At its latest Capital Markets Day, Merck KGaA said that it is “in a strong strategic position” to profit from medium-term growth opportunities in all three of its business sectors after a transitional year in 2023.
At CPHI in Milan in October, eight Indian CDMOs announced that they have formed a trade group to raise the profile of India’s drug services sector and make it a destination of choice.
